TRIAMINIC CHEST & NASAL CONGESTION OTC
Generic Name and Formulations:
Guaifenesin 50mg, phenylephrine HCl 2.5mg; per 5mL; liq; alcohol-free; tropical-flavored; contains sodium 3mg/5mL.
Novartis Consumer Health
Indications for TRIAMINIC CHEST & NASAL CONGESTION:
Cough and nasal congestion.
<4yrs: do not use. 4–6yrs: 5mL. 6–12yrs: 10mL. Repeat every 4 hours as needed; max 6 doses/24 hours.
Children <4yrs old. During or within 14 days of MAOIs.
Hypertension. Cardiovascular disease. Thyroid disease. Diabetes. Asthma. Lower respiratory disorders.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized.
Expectorant + sympathomimetic.
Nervousness, dizziness, insomnia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC